INNO 305
Alternative Names: INNO-305; WT1 heteroclitic peptide immunotherapyLatest Information Update: 29 Sep 2022
Price :
$50 *
At a glance
- Originator Memorial Sloan-Kettering Cancer Center
- Class Cancer vaccines; Peptide vaccines; Peptides
- Mechanism of Action Immunostimulants; Lyn protein-tyrosine kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Acute myeloid leukaemia; Myelodysplastic syndromes; Solid tumours
Most Recent Events
- 23 Sep 2022 CytRx Corporation is now called LadRx Corporation
- 16 Jul 2016 No recent reports of development identified for phase-I development in Acute-myeloid-leukaemia in USA (Parenteral)
- 16 Jul 2016 No recent reports of development identified for phase-I development in Myelodysplastic-syndromes in USA (Parenteral)